Compare Ferrari NV (RACE) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ferrari NV vs State Street SPDR S&P Biotech ETF — how do they compare? Ferrari NV trades at $371.61 (market cap $65.25B), while State Street SPDR S&P Biotech ETF trades at $152.12. The key difference: Ferrari NV pays a 1.14% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Ferrari NV nearer its low. Which is the better fit depends on your goals.
| RACE | XBI | |
|---|---|---|
Market Cap | $65.25B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $517.65 | $164.28 |
52-Week Low | $314.63 | $85.16 |
Enterprise Value | $66.46B | — |
Dividend Yield | 1.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ferrari (RACE) trades at $369.97, down 1.82% today, with a bullish technical outlook supported by moving averages and key support at $370. The company demonstrates strong fundamentals with consistent earnings beats, a 22.19% net margin, and robust cash flow from operations of $2.35B in 2025. Recent news highlights ongoing share buybacks and the upcoming Q2 2026 earnings report on July 30.
The investment outlook remains positive given Ferrari's premium brand positioning, pricing power, and analyst consensus price target of $467.50 implying 26% upside. Risks include execution challenges with new EV models, economic sensitivity, and high valuation multiples. Wall Street sentiment is strongly bullish with 72% buy ratings.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
